SlideShare une entreprise Scribd logo
1  sur  35
Investigation
   Diagnosis
Management
   The prostate is Greek for "protector“ or
    “to stand before” .

   It is an exocrine gland of the male
    reproductive system in most mammals

   In 2002, female paraurethral glands, or
    Skene's glands, were officially renamed
    the female prostate by the Federative
    International Committee on Anatomical
    Terminology
The prostate is a firm, partly gland and partly muscular body, and is
  placed immediately below the internal urethral orifice and around
  the beginning of the urethra.

It is situated in the pelvic cavity, below the lower part of the symphysis
    pubis, above the superior fascia of the urogenital diaphragm, and in
    front of the rectum.

Size of a chestnut and conical in shape

Consist of a base, an apex, an anterior, a posterior and two lateral
  surfaces.
 The base (basis prostatæ) is directed upward, and is attached to the
  inferior surface of the bladder, The greater part of this surface is
  directly continuous with the bladder wall; the urethra penetrates it.
 The apex (apex prostatæ) is directed downward, and is in contact
  with the superior fascia of the urogenital diaphragm
   Vessels and Nerves - The arteries supplying the prostate are
    derived from the internal pudendal, inferior vesical, and
    middle hemorrhoidal. Its veins form a plexus around the
    sides and base of the gland; they receive in front the dorsal
    vein of the penis, and end in the hypogastric veins. The
    nerves are derived from the pelvic plexus
   The "lobe" classification is sometimes used in anatomy.
   Anterior lobe (isthmus) roughly corresponds to part of
    transitional zone. Posterior lobe roughly corresponds to
    peripheral zone. Lateral lobes spans all zones. Median lobe
    (or middle lobe) roughly corresponds to part of central zone

 Peripheral zone: This is the largest zone
and it touches the rectum.

 Transition zone: This is the small, inner part
that wraps around the urethra.
Problems here can pinch the urethra and
make it difficult to pass urine.

Central zone: This refers to the part
between the peripheral and transition zones.
The ejaculatory duct runs through this part.
   It secretes a slightly alkalic fluid, milky in appearance, that usually
    constitutes 50–75% of the volume of the semen along with
    spermatozoa and seminal vesicle fluid.
   Prostate secretion in human consist of proteolytic enzymes,
    prostatic acid phosphatase, beta-microseminoprotein, prostate-
    specific antigen and zinc (more than 500 times concentration than
    in blood!)
    Spermatozoa which was expelled in prostatic fluid have better
    motility, longer survival and better protection of the genetic
    material.
   The prostate also contains some smooth muscles that help expel
    semen during ejaculation
   Testosterone will be transformed into a more active form of
    the hormone, called dihydrotestosterone (DHT) by 5-alpha-
    reductase in the prostate.

   When men gets older, part of the transition zone in the
    prostate which grows throughout lifes will still be reacted to
    the hormone which will cause prostatomegaly.
   Adenomatous prostatic growth is believed to begin at
    approximately age 30 years.
   An estimated 50% of men have histologic evidence of BPH by
    age 50 years and 75% by age 80 years; in 40–50% of these
    men, BPH becomes clinically significant.
   This affect most men over the age of 50 but
    only 10% present with symptoms.

   The severity of symptoms depends on the
    degree of encroachment on the prostatic
    urethra.

   Anatomically, BPH is most strongly
    associated with the posterior urethral glands
    (PUG) and transitional zone (TZ) of the
    prostate.

   However, the majority of growth eventually
    occurs in the TZ.

   Since prostatic cancer also occurs in the PZ,
    BPH nodules in the PZ are often biopsied to
    rule out cancer
The cardinal symptoms are hesitancy and a poor stream.

Other symptoms are :
 nocturia
 Frequency
 Dribbling
 Incontinence
 acute retention
 Haematuria from ruptured dilated bladder neck veins
 Palpable bladder occosianally
 Smell of stale urine in patient
 Enlargement of kidney (hydronephrosis)
 Examination PR - smooth enlarged prostate, median sulcus,
  enlarged lateral lobes.
 Signs of uraemia.
Consist of 7 questions about symptoms and 1 question regarding
  QOL

The 7 symptoms question is marked from 0-5:
 Feeling of incomplete voiding
 Frequency
 Intermittency
 Urgency
 Weak stream
 Straining
 Nocturia


The 8th question of QOL is assigned a score of 0-6

IPSS Result of 7 symptoms question : Total Score of 0-7 (Mildly
  symptomatic) 8-19 (Moderately symptomatic) ; 20-35 (Severely
  symptomatic)
   Suitable for patients where:
    - low risk of progression
    - sx not particularly bothersome

   Regular monitoring using IPSS score will
    objectively identify deterioration

   Education

   Lifestyle advice

   Reassurance
- Per Rectal examination (PR) may reveal a markedly enlarged
    prostate, usually affecting the middle lobe.
    - Blood tests are performed to rule out prostatic malignancy:
    Elevated prostate specific antigen (PSA) levels needs further
    investigations such as reinterpretation of PSA results, in terms of
    PSA density and PSA free percentage, rectal examination and
    transrectal ultrasonography. These combined measures can provide
    early detection.
    - Ultrasound of the testicles, prostate, and kidneys is often
    performed, to rule out malignancy and hydronephrosis.
    - Other blood test and diagnostic procedures for BPH are similar to
    those used for prostate cancer which includes :
   FBC - Hb
   ESR
   RP
   Creatinine
Lifestyle
  Patients should decrease fluid intake before
  bedtime, moderate the consumption of
  alcohol and caffeine-containing products,
  and follow timed voiding schedules.
   The two main medications for management of BPH are alpha blockers and
    5α-reductase inhibitors.

   Commonest alpha blockers used for BPH include doxazosin, terazosin,
    alfuzosin, and tamsulosin

   Alpha blockers relax smooth muscle in the prostate and the bladder neck,
    thus decreasing the blockage of urine flow. Common S/E of alpha blockers
    include orthostatic hypotension, ejaculation changes, nasal congestion, and
    weakness.

   The 5α-reductase inhibitors finasteride and dutasteride effects may take
    longer to appear than alpha blockers, but they persist for many years. S/E
    include decreased libido and ejaculatory or erectile dysfunction.
          Some common drug dose :Prazosin 0.5-10mg BID, Terazosin 1-20mg
          OD, Doxazosin 1-16mg OD, Finasteride 5mg OD
   Antimuscarinics such as tolterodine may also be used,
    especially in combination with alpha blockers.They act by
    decreasing acetylcholine effects on the smooth muscle of the
    bladder, thus helping control symptoms of an overactive
    bladder.

   Sildenafil citrate shows some symptomatic relief, suggesting
    a possible common etiology with erectile dysfunction.
When it is indicated?
 If medical treatment fails, and the patient elects not to try office-based
  therapies or the physician determines the patient is a better candidate for
  transurethral resection of prostate (TURP), surgery may need to be
  performed. In general, TURP is still considered the gold standard of prostate
  interventions for patients that require a procedure. This involves removing
  (part of) the prostate through the urethra.

   Other sriugical option include Transurethral electrovaporization of the
    prostate (TVP), laser TURP, visual laser ablation (VLAP), ethanol injection, and
    others are studied as alternatives.
   Another procedure termed Holmium Laser Ablation of the Prostate (HoLAP)
    has also been gaining acceptance around the world. The penetration depth of
    Holmium lasers is <0.4 mm, so less complications to surround tissues.
   It also carry fewer risks compared with either TURP or open prostatectomy.

   HoLEP is largely similar to the HoLAP procedure; the main difference is that
    this procedure is typically performed on larger prostates. Instead of ablating
    the tissue, the laser cuts a portion of the prostate, which is then cut into
    smaller pieces and flushed with irrigation fluid. As with the HoLAP procedure,
    there is little bleeding during or after the procedure.

   Post surgery care often involves placement of a Foley catheter or a temporary
    prostatic stent to permit healing and allow urine to drain from the bladder
   This is the commonest cancer in men. 52% of tumours at
    presentation are localized to the prostate gland. It is rare below the
    age of 50.
   Most prostate cancers are slow growing; however, there are cases of
    aggressive prostate cancers. The cancer cells may metastasize
    (spread) from the prostate to other parts of the body, particularly
    the bones and lymph nodes.
   Spread occurs to adjacent organs, e.g. bladder, urethra and seminal
    vesicles.
   Spread to the rectum is rare. Lymphatic spread is to the iliac and
    para-aortic nodes. Blood spread occurs early, especially to the
    pelvis, spine and skull (osteosclerotic lesion).
   Prostate cancer may cause pain, difficulty in urinating, problems
    during sexual intercourse, or erectile dysfunction.
Genetic
 Men who have a first-degree relative (father or brother) with
  prostate cancer have twice the risk of developing prostate
  cancer, and those with two first-degree relatives affected
  have a fivefold greater risk compared with men with no family
  history.
 Mutations in BRCA1 and BRCA2, important risk factors for
  ovarian cancer and breast cancer in women, have also been
  implicated in prostate cancer. Other linked genes include the
  Hereditary Prostate cancer gene 1 (HPC1), the androgen
  receptor, and the vitamin D receptor.
Dietary
 Evidence supports little role for dietary fruits and vegetables
  in prostate cancer occurrence.
 Red meat and processed meat also appear to have little effect
  in human studies. Higher meat consumption has been
  associated with a higher risk in some studies.
 Lower blood levels of vitamin D may increase the risk of
  developing prostate cancer.
 Taking multivitamins more than seven times a week may
  increase the risk of developing the disease.
 A 2009 study on folic acid supplements showed an
  association with an increased risk of developing prostate
  cancer.
 Obesity and elevated blood levels of testosterone may
  increase the risk for prostate cancer.
Others
 Use of the cholesterol-lowering drugs ( statins )may also decrease
  prostate cancer risk.

   Infection or inflammation of the prostate (prostatitis) may increase
    the chance for prostate.sexually transmitted infections chlamydia,
    gonorrhea, or syphilis seems to increase risk.

   There is an association between vasectomy and prostate cancer
    however more research is needed to determine if this is a causative
    relationship.
   Asymptomatic
   Hard craggy mass and nodule in prostate on rectal examination
    - the median sulcus between the lobes may be obliterated
   Incontinence
   Dysuria
   Haematuria
   Hesitancy
   Dribbling
   Retention
   Bone pain - pathological fractures
   Sciatica
   Anaemia
   Weight loss
   Palpable bladder
   Tenderness over bone
   Hepatomegaly
   Hb-FBC
   ESR
   U&Es
   Creatinine
   PSA - PSA Density (PSAD) - the blood PSA level divided by the size of the
    prostate, as determined by TRUS - can help distinguish between BPH and
    prostate cancer. Basically, with BPH, the PSA level should not be more
    than 15 percent of the size of the prostate. PSA levels exceeding 15
    percent of the size of the prostate are more likely to indicate the
    presence of prostate cancer -- and the need for a biopsy.
   Transrectal Ultrasound (TRUS) scan and guided biopsy
   CXR : metastases in lungs or ribs
   Bone radiograph : sclerotic deposits in pelvis, spine or skull
   Bone scan is sensitive indicator of early metastases
   Ultrasound Spectral (USS) : residual urine, upper urinary tract
      obstruction, and useful in prostate Ca grading.

    Grade   I - 3.0 to 3.8 cms 30 Gms.
    Grade   II - 3.8 to 4.5 cms 30- 50 Gms.
    Grade   III- 4.5 to 5.5 cms 50- 80 Gms.
    Grade   IV - 5.5. cms 85 Gms
   Is used to help evaluate the prognosis of men with prostate
    cancer.

   It grades tumors on a scale of 1-5. You may have different
    grades of ca in one biopsy sampel.

   The 2 main grades are added together.
    - The higher the score,the higher the probability of the ca to
    spread past the prostate.
   Scores 2-5 : Low grade prostate
   Scores 6-7 : Intermedieate (most prostate fall into this group)
   Scores 8-10:High grade ca
Mainly TURP to relieve obstructive symptoms
Other treatment for Prostatic Cancer depends on staging.
 For cancer localized to prostate - observation with routine monitoring of
  PSA, external beam radiotherapy or radical prostatectomy.
 For metastatic disease, hormonal manipulation is used, such as
  Luteinizing releasing hormone releasing hormone (LHRH) agonist E.g.
  cyproterone acetate or bicalutamide and silboestrol,which is rarely used
  nowadays (causes gynaecomastioa and fluid retention)
 Local radiotherapy is used for bony metastatic pain



PROGNOSIS :
  Variable - Depends on stage at presentation. Patients with clinically
  localized tumor treated radically may expect a normal life expectancy.
  Those with metastatic disease at presentation have a median 3-year
  survival.
   This occurs most commonly in young adults.
   Acute bacterial prostatitis ususally presents as an
    acute febrile illness.
   Chronic prostatitis presents with recurrent UTIs.
   If there is a past history of TB anywhere in the
    body, suspect TB prostatitis.
Acute Bacterial Prostatitis :
 Fever
 Low back pain
 Perineal pain
 Bladder irritation
 Outflow obstruction
 Enlarged tender prostate


Chronic Prostatitis :
 Sx of UTI - but mild or sometimes absent
 Dull perineal ache
 Normal or indurated irregular prostate
Acute Prostatitis :
 FBC - TWC (raised)

 Mid -stream urine (MSU) - shows growth.

 Blood C&S

  Common bacterias are:
  Echerichiacoli, Klebsiella, Proteus, Pseudomonas, Enterobacter, Ente
  rococcus, Serratia, andStaphylococcus aureus

Chronic Prostatitis :
 Prostatic massage may yield secretions containing white cells
  and occasionally orgasms
 Culture for TB in chronic prostatitis
Acute Prostatitis :
 Bed rest
 Hydration
 Antibiotics (I.V) eg. Ciprofloxacin, Co-trimoxazole and
  tetracyclines such as doxycycline
 Analgesics
 Patients with urinary retention are best managed with a
  suprapubic catheter or intermittent catheterization.

Chronic Prostatitis :
 Long term antibiotics eg. Ciprofoloxacin for 4-8weeks
 Escherichia coli extract and cranberry have a
potentially preventive effect
 Prostatic massage (may be effective)


TB Prostatitis :
 Anti - TB
   What is prostate?
   What prostate does?
   What are the causes for enlargement of
    prostate?
   How do we differentiate between each
    cause?
   What are the treatment of BPH, Prostate
    Ca and Prostatitis?
   Churchill’s Surgery
   Oxford Clinical Surgery
   World Wide Web
The Prostate Gland: Investigation, Diagnosis and Management

Contenu connexe

Tendances (20)

Testicular Torsion
Testicular TorsionTesticular Torsion
Testicular Torsion
 
Inguinal hernia ppt
Inguinal hernia pptInguinal hernia ppt
Inguinal hernia ppt
 
Obstructive jaundice.
Obstructive jaundice.Obstructive jaundice.
Obstructive jaundice.
 
carcinoma of stomach
 carcinoma of  stomach carcinoma of  stomach
carcinoma of stomach
 
Varicocele
VaricoceleVaricocele
Varicocele
 
Soft tissue sarcoma
Soft tissue sarcomaSoft tissue sarcoma
Soft tissue sarcoma
 
Carcinoma rectum (Rectal Cancer)
Carcinoma rectum (Rectal Cancer)Carcinoma rectum (Rectal Cancer)
Carcinoma rectum (Rectal Cancer)
 
Obstructive jaundice
Obstructive jaundiceObstructive jaundice
Obstructive jaundice
 
Anal Fissure
Anal FissureAnal Fissure
Anal Fissure
 
Intussusception
IntussusceptionIntussusception
Intussusception
 
Inguinal hernia
Inguinal herniaInguinal hernia
Inguinal hernia
 
Hydrocele management
Hydrocele managementHydrocele management
Hydrocele management
 
Haematuria
HaematuriaHaematuria
Haematuria
 
Fibroadenoma
FibroadenomaFibroadenoma
Fibroadenoma
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Prostate cancer
Prostate cancerProstate cancer
Prostate cancer
 
Gas Under Diaphragm - Final Year MB BS Lecture
Gas Under Diaphragm - Final Year MB BS LectureGas Under Diaphragm - Final Year MB BS Lecture
Gas Under Diaphragm - Final Year MB BS Lecture
 
ANDI & benign breast disorders
ANDI & benign breast disordersANDI & benign breast disorders
ANDI & benign breast disorders
 
sebaceous cyst
sebaceous cystsebaceous cyst
sebaceous cyst
 
Hypothyroidism
HypothyroidismHypothyroidism
Hypothyroidism
 

En vedette

Benign Enlargement Of The Prostate
Benign Enlargement Of The ProstateBenign Enlargement Of The Prostate
Benign Enlargement Of The ProstateSoumar Dutta
 
How is prostate cancer diagnosed?
How is prostate cancer diagnosed?How is prostate cancer diagnosed?
How is prostate cancer diagnosed?Marc Laniado
 
Prostrate Enlargement-Must read for men above 40
Prostrate Enlargement-Must read for men above 40Prostrate Enlargement-Must read for men above 40
Prostrate Enlargement-Must read for men above 40Col Mukteshwar Prasad
 
Benign & Malignant Diseases Of The Prostate
Benign &  Malignant  Diseases  Of  The  Prostate Benign &  Malignant  Diseases  Of  The  Prostate
Benign & Malignant Diseases Of The Prostate Sodo
 
CARCINOMA PROSTATE- Dr Manoj Kumar B, PGI
CARCINOMA PROSTATE- Dr Manoj Kumar B, PGICARCINOMA PROSTATE- Dr Manoj Kumar B, PGI
CARCINOMA PROSTATE- Dr Manoj Kumar B, PGIPGIMER, AIIMS
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasiaSam Msigwa
 
Evaluation of the patient with benign Prostatic Hyperplasia(BPH)
Evaluation of the patient with benign Prostatic Hyperplasia(BPH)Evaluation of the patient with benign Prostatic Hyperplasia(BPH)
Evaluation of the patient with benign Prostatic Hyperplasia(BPH)Labib Mortuza
 
Benign Prostate Hypertrophy for nursing students
Benign Prostate Hypertrophy for nursing studentsBenign Prostate Hypertrophy for nursing students
Benign Prostate Hypertrophy for nursing studentsPreeths Roshan
 
Ca prostate [edmond]
Ca prostate [edmond]Ca prostate [edmond]
Ca prostate [edmond]Edmond Wong
 
Ultrasound breast mass
Ultrasound breast massUltrasound breast mass
Ultrasound breast massREKHAKHARE
 
Uterus pathology
Uterus pathology Uterus pathology
Uterus pathology Mona Rashed
 
Carcinoma of breast
Carcinoma of breastCarcinoma of breast
Carcinoma of breastSaurav Singh
 
Etiology and pathophysiology of bph
Etiology and pathophysiology of bphEtiology and pathophysiology of bph
Etiology and pathophysiology of bphAhmed Eliwa
 

En vedette (20)

Benign Enlargement Of The Prostate
Benign Enlargement Of The ProstateBenign Enlargement Of The Prostate
Benign Enlargement Of The Prostate
 
How is prostate cancer diagnosed?
How is prostate cancer diagnosed?How is prostate cancer diagnosed?
How is prostate cancer diagnosed?
 
Prostrate Enlargement-Must read for men above 40
Prostrate Enlargement-Must read for men above 40Prostrate Enlargement-Must read for men above 40
Prostrate Enlargement-Must read for men above 40
 
Benign & Malignant Diseases Of The Prostate
Benign &  Malignant  Diseases  Of  The  Prostate Benign &  Malignant  Diseases  Of  The  Prostate
Benign & Malignant Diseases Of The Prostate
 
Pathology of Prostate
Pathology of ProstatePathology of Prostate
Pathology of Prostate
 
Benign Prostatic Hyperplasia
Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
 
Pathology of Prostate - Benign
Pathology of Prostate - BenignPathology of Prostate - Benign
Pathology of Prostate - Benign
 
CARCINOMA PROSTATE- Dr Manoj Kumar B, PGI
CARCINOMA PROSTATE- Dr Manoj Kumar B, PGICARCINOMA PROSTATE- Dr Manoj Kumar B, PGI
CARCINOMA PROSTATE- Dr Manoj Kumar B, PGI
 
BPH
BPHBPH
BPH
 
Prostate Cancer
Prostate CancerProstate Cancer
Prostate Cancer
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasia
 
Evaluation of the patient with benign Prostatic Hyperplasia(BPH)
Evaluation of the patient with benign Prostatic Hyperplasia(BPH)Evaluation of the patient with benign Prostatic Hyperplasia(BPH)
Evaluation of the patient with benign Prostatic Hyperplasia(BPH)
 
NAFLD
NAFLDNAFLD
NAFLD
 
Bi Rads Breast
Bi Rads BreastBi Rads Breast
Bi Rads Breast
 
Benign Prostate Hypertrophy for nursing students
Benign Prostate Hypertrophy for nursing studentsBenign Prostate Hypertrophy for nursing students
Benign Prostate Hypertrophy for nursing students
 
Ca prostate [edmond]
Ca prostate [edmond]Ca prostate [edmond]
Ca prostate [edmond]
 
Ultrasound breast mass
Ultrasound breast massUltrasound breast mass
Ultrasound breast mass
 
Uterus pathology
Uterus pathology Uterus pathology
Uterus pathology
 
Carcinoma of breast
Carcinoma of breastCarcinoma of breast
Carcinoma of breast
 
Etiology and pathophysiology of bph
Etiology and pathophysiology of bphEtiology and pathophysiology of bph
Etiology and pathophysiology of bph
 

Similaire à The Prostate Gland: Investigation, Diagnosis and Management

Bph and prostate cancer
Bph and prostate cancerBph and prostate cancer
Bph and prostate cancerOrhan Hakli
 
Bph presentation
Bph presentationBph presentation
Bph presentationdolten1382
 
Benign Prostate Hypertrophy
Benign Prostate HypertrophyBenign Prostate Hypertrophy
Benign Prostate HypertrophyRutviPatel25
 
Dutasteride presentation
Dutasteride presentationDutasteride presentation
Dutasteride presentationPabitra Thapa
 
Benign Prostatic Hyperplasia Msigwa
Benign Prostatic Hyperplasia MsigwaBenign Prostatic Hyperplasia Msigwa
Benign Prostatic Hyperplasia MsigwaSam Msigwa
 
Prostate Anatomy,physiology & Pathology
Prostate Anatomy,physiology & PathologyProstate Anatomy,physiology & Pathology
Prostate Anatomy,physiology & PathologyFaisal Azmi
 
Presentation1.pptx, radiological imaging of prostatic diseases
Presentation1.pptx, radiological imaging of prostatic diseasesPresentation1.pptx, radiological imaging of prostatic diseases
Presentation1.pptx, radiological imaging of prostatic diseasesAbdellah Nazeer
 
Benign prostatic hypertrophy
Benign prostatic hypertrophyBenign prostatic hypertrophy
Benign prostatic hypertrophyrahulverma1194
 
benignprostatichypertrophy.pdf
benignprostatichypertrophy.pdfbenignprostatichypertrophy.pdf
benignprostatichypertrophy.pdfAugustusCaesar7
 
Benign malignant-diseases-of-the-prostate-1196345186460377-3
Benign malignant-diseases-of-the-prostate-1196345186460377-3Benign malignant-diseases-of-the-prostate-1196345186460377-3
Benign malignant-diseases-of-the-prostate-1196345186460377-3patientfocus
 
BPH- Pathology & Investigations
BPH- Pathology & InvestigationsBPH- Pathology & Investigations
BPH- Pathology & InvestigationsAnkur Agarwal
 
Benign & Malignant Diseases Of The Prostate Saud
Benign &  Malignant  Diseases  Of  The  Prostate SaudBenign &  Malignant  Diseases  Of  The  Prostate Saud
Benign & Malignant Diseases Of The Prostate SaudSodo
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasiaSandeep Patil
 
BPH & its management by Dr Nesar
BPH & its management by Dr NesarBPH & its management by Dr Nesar
BPH & its management by Dr NesarStudent
 

Similaire à The Prostate Gland: Investigation, Diagnosis and Management (20)

Pathology of prostate
Pathology of prostatePathology of prostate
Pathology of prostate
 
Bph and prostate cancer
Bph and prostate cancerBph and prostate cancer
Bph and prostate cancer
 
Bph presentation
Bph presentationBph presentation
Bph presentation
 
Bph presentation
Bph presentationBph presentation
Bph presentation
 
Benign Prostate Hypertrophy
Benign Prostate HypertrophyBenign Prostate Hypertrophy
Benign Prostate Hypertrophy
 
Dutasteride presentation
Dutasteride presentationDutasteride presentation
Dutasteride presentation
 
Prostate
ProstateProstate
Prostate
 
Prostate
ProstateProstate
Prostate
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasia
 
Benign Prostatic Hyperplasia Msigwa
Benign Prostatic Hyperplasia MsigwaBenign Prostatic Hyperplasia Msigwa
Benign Prostatic Hyperplasia Msigwa
 
Prostate Anatomy,physiology & Pathology
Prostate Anatomy,physiology & PathologyProstate Anatomy,physiology & Pathology
Prostate Anatomy,physiology & Pathology
 
Presentation1.pptx, radiological imaging of prostatic diseases
Presentation1.pptx, radiological imaging of prostatic diseasesPresentation1.pptx, radiological imaging of prostatic diseases
Presentation1.pptx, radiological imaging of prostatic diseases
 
Benign prostatic hypertrophy
Benign prostatic hypertrophyBenign prostatic hypertrophy
Benign prostatic hypertrophy
 
benignprostatichypertrophy.pdf
benignprostatichypertrophy.pdfbenignprostatichypertrophy.pdf
benignprostatichypertrophy.pdf
 
Ca prostate
Ca prostateCa prostate
Ca prostate
 
Benign malignant-diseases-of-the-prostate-1196345186460377-3
Benign malignant-diseases-of-the-prostate-1196345186460377-3Benign malignant-diseases-of-the-prostate-1196345186460377-3
Benign malignant-diseases-of-the-prostate-1196345186460377-3
 
BPH- Pathology & Investigations
BPH- Pathology & InvestigationsBPH- Pathology & Investigations
BPH- Pathology & Investigations
 
Benign & Malignant Diseases Of The Prostate Saud
Benign &  Malignant  Diseases  Of  The  Prostate SaudBenign &  Malignant  Diseases  Of  The  Prostate Saud
Benign & Malignant Diseases Of The Prostate Saud
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasia
 
BPH & its management by Dr Nesar
BPH & its management by Dr NesarBPH & its management by Dr Nesar
BPH & its management by Dr Nesar
 

The Prostate Gland: Investigation, Diagnosis and Management

  • 1. Investigation Diagnosis Management
  • 2. The prostate is Greek for "protector“ or “to stand before” .  It is an exocrine gland of the male reproductive system in most mammals  In 2002, female paraurethral glands, or Skene's glands, were officially renamed the female prostate by the Federative International Committee on Anatomical Terminology
  • 3. The prostate is a firm, partly gland and partly muscular body, and is placed immediately below the internal urethral orifice and around the beginning of the urethra. It is situated in the pelvic cavity, below the lower part of the symphysis pubis, above the superior fascia of the urogenital diaphragm, and in front of the rectum. Size of a chestnut and conical in shape Consist of a base, an apex, an anterior, a posterior and two lateral surfaces.  The base (basis prostatæ) is directed upward, and is attached to the inferior surface of the bladder, The greater part of this surface is directly continuous with the bladder wall; the urethra penetrates it.  The apex (apex prostatæ) is directed downward, and is in contact with the superior fascia of the urogenital diaphragm
  • 4. Vessels and Nerves - The arteries supplying the prostate are derived from the internal pudendal, inferior vesical, and middle hemorrhoidal. Its veins form a plexus around the sides and base of the gland; they receive in front the dorsal vein of the penis, and end in the hypogastric veins. The nerves are derived from the pelvic plexus
  • 5. The "lobe" classification is sometimes used in anatomy.  Anterior lobe (isthmus) roughly corresponds to part of transitional zone. Posterior lobe roughly corresponds to peripheral zone. Lateral lobes spans all zones. Median lobe (or middle lobe) roughly corresponds to part of central zone  Peripheral zone: This is the largest zone and it touches the rectum.  Transition zone: This is the small, inner part that wraps around the urethra. Problems here can pinch the urethra and make it difficult to pass urine. Central zone: This refers to the part between the peripheral and transition zones. The ejaculatory duct runs through this part.
  • 6. It secretes a slightly alkalic fluid, milky in appearance, that usually constitutes 50–75% of the volume of the semen along with spermatozoa and seminal vesicle fluid.  Prostate secretion in human consist of proteolytic enzymes, prostatic acid phosphatase, beta-microseminoprotein, prostate- specific antigen and zinc (more than 500 times concentration than in blood!)  Spermatozoa which was expelled in prostatic fluid have better motility, longer survival and better protection of the genetic material.  The prostate also contains some smooth muscles that help expel semen during ejaculation
  • 7. Testosterone will be transformed into a more active form of the hormone, called dihydrotestosterone (DHT) by 5-alpha- reductase in the prostate.  When men gets older, part of the transition zone in the prostate which grows throughout lifes will still be reacted to the hormone which will cause prostatomegaly.  Adenomatous prostatic growth is believed to begin at approximately age 30 years.  An estimated 50% of men have histologic evidence of BPH by age 50 years and 75% by age 80 years; in 40–50% of these men, BPH becomes clinically significant.
  • 8. This affect most men over the age of 50 but only 10% present with symptoms.  The severity of symptoms depends on the degree of encroachment on the prostatic urethra.  Anatomically, BPH is most strongly associated with the posterior urethral glands (PUG) and transitional zone (TZ) of the prostate.  However, the majority of growth eventually occurs in the TZ.  Since prostatic cancer also occurs in the PZ, BPH nodules in the PZ are often biopsied to rule out cancer
  • 9.
  • 10. The cardinal symptoms are hesitancy and a poor stream. Other symptoms are :  nocturia  Frequency  Dribbling  Incontinence  acute retention  Haematuria from ruptured dilated bladder neck veins  Palpable bladder occosianally  Smell of stale urine in patient  Enlargement of kidney (hydronephrosis)  Examination PR - smooth enlarged prostate, median sulcus, enlarged lateral lobes.  Signs of uraemia.
  • 11. Consist of 7 questions about symptoms and 1 question regarding QOL The 7 symptoms question is marked from 0-5:  Feeling of incomplete voiding  Frequency  Intermittency  Urgency  Weak stream  Straining  Nocturia The 8th question of QOL is assigned a score of 0-6 IPSS Result of 7 symptoms question : Total Score of 0-7 (Mildly symptomatic) 8-19 (Moderately symptomatic) ; 20-35 (Severely symptomatic)
  • 12. Suitable for patients where: - low risk of progression - sx not particularly bothersome  Regular monitoring using IPSS score will objectively identify deterioration  Education  Lifestyle advice  Reassurance
  • 13. - Per Rectal examination (PR) may reveal a markedly enlarged prostate, usually affecting the middle lobe. - Blood tests are performed to rule out prostatic malignancy: Elevated prostate specific antigen (PSA) levels needs further investigations such as reinterpretation of PSA results, in terms of PSA density and PSA free percentage, rectal examination and transrectal ultrasonography. These combined measures can provide early detection. - Ultrasound of the testicles, prostate, and kidneys is often performed, to rule out malignancy and hydronephrosis. - Other blood test and diagnostic procedures for BPH are similar to those used for prostate cancer which includes :  FBC - Hb  ESR  RP  Creatinine
  • 14. Lifestyle Patients should decrease fluid intake before bedtime, moderate the consumption of alcohol and caffeine-containing products, and follow timed voiding schedules.
  • 15. The two main medications for management of BPH are alpha blockers and 5α-reductase inhibitors.  Commonest alpha blockers used for BPH include doxazosin, terazosin, alfuzosin, and tamsulosin  Alpha blockers relax smooth muscle in the prostate and the bladder neck, thus decreasing the blockage of urine flow. Common S/E of alpha blockers include orthostatic hypotension, ejaculation changes, nasal congestion, and weakness.  The 5α-reductase inhibitors finasteride and dutasteride effects may take longer to appear than alpha blockers, but they persist for many years. S/E include decreased libido and ejaculatory or erectile dysfunction. Some common drug dose :Prazosin 0.5-10mg BID, Terazosin 1-20mg OD, Doxazosin 1-16mg OD, Finasteride 5mg OD
  • 16. Antimuscarinics such as tolterodine may also be used, especially in combination with alpha blockers.They act by decreasing acetylcholine effects on the smooth muscle of the bladder, thus helping control symptoms of an overactive bladder.  Sildenafil citrate shows some symptomatic relief, suggesting a possible common etiology with erectile dysfunction.
  • 17. When it is indicated?  If medical treatment fails, and the patient elects not to try office-based therapies or the physician determines the patient is a better candidate for transurethral resection of prostate (TURP), surgery may need to be performed. In general, TURP is still considered the gold standard of prostate interventions for patients that require a procedure. This involves removing (part of) the prostate through the urethra.  Other sriugical option include Transurethral electrovaporization of the prostate (TVP), laser TURP, visual laser ablation (VLAP), ethanol injection, and others are studied as alternatives.
  • 18. Another procedure termed Holmium Laser Ablation of the Prostate (HoLAP) has also been gaining acceptance around the world. The penetration depth of Holmium lasers is <0.4 mm, so less complications to surround tissues.  It also carry fewer risks compared with either TURP or open prostatectomy.  HoLEP is largely similar to the HoLAP procedure; the main difference is that this procedure is typically performed on larger prostates. Instead of ablating the tissue, the laser cuts a portion of the prostate, which is then cut into smaller pieces and flushed with irrigation fluid. As with the HoLAP procedure, there is little bleeding during or after the procedure.  Post surgery care often involves placement of a Foley catheter or a temporary prostatic stent to permit healing and allow urine to drain from the bladder
  • 19. This is the commonest cancer in men. 52% of tumours at presentation are localized to the prostate gland. It is rare below the age of 50.  Most prostate cancers are slow growing; however, there are cases of aggressive prostate cancers. The cancer cells may metastasize (spread) from the prostate to other parts of the body, particularly the bones and lymph nodes.  Spread occurs to adjacent organs, e.g. bladder, urethra and seminal vesicles.  Spread to the rectum is rare. Lymphatic spread is to the iliac and para-aortic nodes. Blood spread occurs early, especially to the pelvis, spine and skull (osteosclerotic lesion).  Prostate cancer may cause pain, difficulty in urinating, problems during sexual intercourse, or erectile dysfunction.
  • 20. Genetic  Men who have a first-degree relative (father or brother) with prostate cancer have twice the risk of developing prostate cancer, and those with two first-degree relatives affected have a fivefold greater risk compared with men with no family history.  Mutations in BRCA1 and BRCA2, important risk factors for ovarian cancer and breast cancer in women, have also been implicated in prostate cancer. Other linked genes include the Hereditary Prostate cancer gene 1 (HPC1), the androgen receptor, and the vitamin D receptor.
  • 21. Dietary  Evidence supports little role for dietary fruits and vegetables in prostate cancer occurrence.  Red meat and processed meat also appear to have little effect in human studies. Higher meat consumption has been associated with a higher risk in some studies.  Lower blood levels of vitamin D may increase the risk of developing prostate cancer.  Taking multivitamins more than seven times a week may increase the risk of developing the disease.  A 2009 study on folic acid supplements showed an association with an increased risk of developing prostate cancer.  Obesity and elevated blood levels of testosterone may increase the risk for prostate cancer.
  • 22. Others  Use of the cholesterol-lowering drugs ( statins )may also decrease prostate cancer risk.  Infection or inflammation of the prostate (prostatitis) may increase the chance for prostate.sexually transmitted infections chlamydia, gonorrhea, or syphilis seems to increase risk.  There is an association between vasectomy and prostate cancer however more research is needed to determine if this is a causative relationship.
  • 23. Asymptomatic  Hard craggy mass and nodule in prostate on rectal examination - the median sulcus between the lobes may be obliterated  Incontinence  Dysuria  Haematuria  Hesitancy  Dribbling  Retention  Bone pain - pathological fractures  Sciatica  Anaemia  Weight loss  Palpable bladder  Tenderness over bone  Hepatomegaly
  • 24. Hb-FBC  ESR  U&Es  Creatinine  PSA - PSA Density (PSAD) - the blood PSA level divided by the size of the prostate, as determined by TRUS - can help distinguish between BPH and prostate cancer. Basically, with BPH, the PSA level should not be more than 15 percent of the size of the prostate. PSA levels exceeding 15 percent of the size of the prostate are more likely to indicate the presence of prostate cancer -- and the need for a biopsy.  Transrectal Ultrasound (TRUS) scan and guided biopsy  CXR : metastases in lungs or ribs  Bone radiograph : sclerotic deposits in pelvis, spine or skull  Bone scan is sensitive indicator of early metastases  Ultrasound Spectral (USS) : residual urine, upper urinary tract obstruction, and useful in prostate Ca grading. Grade I - 3.0 to 3.8 cms 30 Gms. Grade II - 3.8 to 4.5 cms 30- 50 Gms. Grade III- 4.5 to 5.5 cms 50- 80 Gms. Grade IV - 5.5. cms 85 Gms
  • 25. Is used to help evaluate the prognosis of men with prostate cancer.  It grades tumors on a scale of 1-5. You may have different grades of ca in one biopsy sampel.  The 2 main grades are added together. - The higher the score,the higher the probability of the ca to spread past the prostate.  Scores 2-5 : Low grade prostate  Scores 6-7 : Intermedieate (most prostate fall into this group)  Scores 8-10:High grade ca
  • 26. Mainly TURP to relieve obstructive symptoms Other treatment for Prostatic Cancer depends on staging.  For cancer localized to prostate - observation with routine monitoring of PSA, external beam radiotherapy or radical prostatectomy.  For metastatic disease, hormonal manipulation is used, such as Luteinizing releasing hormone releasing hormone (LHRH) agonist E.g. cyproterone acetate or bicalutamide and silboestrol,which is rarely used nowadays (causes gynaecomastioa and fluid retention)  Local radiotherapy is used for bony metastatic pain PROGNOSIS : Variable - Depends on stage at presentation. Patients with clinically localized tumor treated radically may expect a normal life expectancy. Those with metastatic disease at presentation have a median 3-year survival.
  • 27.
  • 28.
  • 29. This occurs most commonly in young adults.  Acute bacterial prostatitis ususally presents as an acute febrile illness.  Chronic prostatitis presents with recurrent UTIs.  If there is a past history of TB anywhere in the body, suspect TB prostatitis.
  • 30. Acute Bacterial Prostatitis :  Fever  Low back pain  Perineal pain  Bladder irritation  Outflow obstruction  Enlarged tender prostate Chronic Prostatitis :  Sx of UTI - but mild or sometimes absent  Dull perineal ache  Normal or indurated irregular prostate
  • 31. Acute Prostatitis :  FBC - TWC (raised)  Mid -stream urine (MSU) - shows growth.  Blood C&S Common bacterias are: Echerichiacoli, Klebsiella, Proteus, Pseudomonas, Enterobacter, Ente rococcus, Serratia, andStaphylococcus aureus Chronic Prostatitis :  Prostatic massage may yield secretions containing white cells and occasionally orgasms  Culture for TB in chronic prostatitis
  • 32. Acute Prostatitis :  Bed rest  Hydration  Antibiotics (I.V) eg. Ciprofloxacin, Co-trimoxazole and tetracyclines such as doxycycline  Analgesics  Patients with urinary retention are best managed with a suprapubic catheter or intermittent catheterization. Chronic Prostatitis :  Long term antibiotics eg. Ciprofoloxacin for 4-8weeks  Escherichia coli extract and cranberry have a potentially preventive effect  Prostatic massage (may be effective) TB Prostatitis :  Anti - TB
  • 33. What is prostate?  What prostate does?  What are the causes for enlargement of prostate?  How do we differentiate between each cause?  What are the treatment of BPH, Prostate Ca and Prostatitis?
  • 34. Churchill’s Surgery  Oxford Clinical Surgery  World Wide Web